中国临床药学杂志

目的 观察CapeOx方案联合呋喹替尼治疗晚期微卫星稳定(MSS)型结直肠癌(CRC)的疗效及安全性。方法 选择2021年9月-2023年9月本院收治的晚期MSS型CRC患者80例，按照随机数字表法分为2组：对照组40例，予CapeOx方案(奥沙利铂+卡培他滨)治疗；研究组40例，予CapeOx方案(奥沙利铂+卡培他滨)联合呋喹替尼治疗。比较2组疗效、肿瘤标志物、免疫指标、血管生成相关指标、炎症反应、安全性和生存率。结果 研究组的客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(P<0.05)。治疗后，2组的癌胚抗原、糖类抗原19-9、血管内皮生长因子(VEGF)、白细胞介素-8(IL-8)、C反应蛋白(CRP)、中性粒细胞与淋巴细胞比值(NLR)均低于治疗前，且低于对照组(P<0.05)。治疗后，研究组的CD3⁺、CD4⁺高于治疗前，且高于对照组(P<0.05)。各不良反应发生率在2组间比较差异无统计学意义(P > 0.05)。研究组1年生存率(90.00%,36/40)高于对照组(72.50%,29/40)，且2组生存曲线比较差异有统计学意义(Log-rankχ2=4.077,P<0.05)。结论 呋喹替尼辅助治疗晚期MSS型CRC疗效肯定，可提高ORR、DCR和1年生存率，调节肿瘤标志物、免疫指标及血管生成相关指标，减轻炎症反应，安全性良好。

AIM To observe the efficacy and safety of CapeOx regimen combined with fruquintinib on advanced microsatellite stable(MSS) colorectal cancer(CRC). METHODS From September 2021 to September 2023, 80 patients with advanced MSS CRC who visited our hospital were grouped through random number table. The control group(n=40) performed CapeOx regimen(oxaliplatin+capecitabine), while the research group(n=40) performed the CapeOx regimen(oxaliplatin+capecitabine) combined with fruquintinib. Efficacy, tumor markers, immune indicators, angiogenesis-related indicators, inflammatory response, security, and survival rate were compared between 2 groups. RESULTS The research group had higher objective response rate(ORR) and disease control rate(DCR) than the control group(P < 0.05). Both groups showed reduced levels of carcinoembryonic antigen, carbohydrate antigen 19-9, vascular endothelial growth factor(VEGF), interleukin-8(IL-8), C-reactive protein(CRP), and neutrophil to lymphocyte ratio(NLR) after treatment, with the research group showing lower levels than the control group(P < 0.05). After treatment, the research group had higher CD3⁺ and CD4⁺ counts compared to prior treatment, and the research group's counts were higher than those of the control group(P < 0.05). There was no statistically significant difference in adverse reactions between the 2 groups(P > 0.05).The research group had a higher 1-year survival rate(90.00%, 36/40) than the control group(72.50%, 29/40), and the difference in survival curves between the 2 groups was statistically significant(Log rank χ2=4.077, P < 0.05). CONCLUSION Fruquintinib as an adjuvant therapy for advanced MSS CRC has definite efficacy. It could improve ORR, DCR and 1-year survival rate, regulate tumor markers, immune indicators and angiogenesis-related indicators, alleviate inflammatory response, and demonstrates good safety.